DFTX

#1289
Definium Therapeutics, Inc. - Common Shares
40.9 8 USD
-0.06%
Market Price
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
40.98
40.98
Year Range
14.62
49.70
Daily Change
-6.48%
Monthly Change
-8.89%
6 month change
+144.51%
Year Change
+171.21%
Previous Close
43.8 2
Open
40.9 8
Low
40.9 8
High
40.9 8
Volume
196
Open full chart

Financials

Overview Statement Statistics Documents

2026

Current report, Q3 FY2026
Definium Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Definium Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Definium Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Definium Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Definium Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Definium Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Definium Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Definium Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Definium Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Definium Therapeutics, Inc. current report, Q2 FY2026
8-K

Definium Therapeutics, Inc. current report, Q2 FY2022

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by Mind Medicine (MindMed) Inc. on May 23, 2022. The filing discloses the appointment of Schond Greenway as the Company's Chief Financial Officer, effective immediately on the filing date. The Company is incorporated in British Columbia, Canada, and its Subordinate Voting Shares trade on The Nasdaq Stock Market LLC under the symbol MNMD.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointment details rather than financial performance.

Material Changes

The primary material change reported is the appointment of Schond Greenway as Chief Financial Officer. Mr. Greenway replaces the previous principal financial officer and brings prior experience as CFO of Avalo Therapeutics, Inc., and in investor relations roles at Mesoblast Limited and Halozyme Therapeutics, Inc.

Compensation and Management Commentary

Under the terms of the Offer Letter, Mr. Greenway's compensation package includes:

  • Base Salary: $400,000 annually.
  • Cash Bonus: Discretionary annual bonus with a target of 40% of base salary.
  • Equity Awards:
    • Option to purchase 1,650,000 Subordinate Voting Shares at the closing price on May 23, 2022.
    • Restricted Stock Unit (RSU) award for 1,270,000 Subordinate Voting Shares.
  • Vesting Schedule: Both the option and RSU awards vest over four years. 25% vests on the first anniversary of the Effective Date, with the remainder vesting monthly (options) or quarterly (RSUs) thereafter, subject to continuous service.

Employment is at-will and may be terminated by either party at any time. The full Offer Letter is to be filed as an exhibit to the Company's Form 10-Q for the quarter ending June 30, 2022.

Investor Verification Checklist

  • Verify the closing price of MNMD shares on May 23, 2022, to calculate the exercise price of the 1,650,000 stock options.
  • Review the upcoming Form 10-Q (due for the quarter ending June 30, 2022) for the full text of the Offer Letter and any additional compensation terms.
  • Monitor future filings for any changes in the Company's financial leadership or strategy resulting from the new CFO's tenure.
  • Confirm the Company's cash position in subsequent financial reports to assess the ability to fund the new executive's salary and potential bonus obligations.